INSM Q3 2024 Earnings — Insmed Incorporated Revenue & Financial Results | Market Cap Arena

INSMInsmed Incorporated

$31B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$93M+18.2% YoY

Gross Profit

$72M77.3% margin

Operating Income

-$213M-228.4% margin

Net Income

-$221M-236.0% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

-$181M

Free Cash Flow

-$185M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$1.6B

Stockholders' Equity

$483M

Cash & Equivalents

$461M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93M	$79M	+18.2%
Gross Profit	$72M	$62M	+15.9%
Operating Income	-$213M	-$148M	-44.5%
Net Income	-$221M	-$159M	-38.8%

Geographic Segments

UNITED STATES

$67M72%

JAPAN

$21M22%

Europe And The Rest Of The World

$6M6%